Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMe2031382 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease.
Egypt Heart J
December 2024
Department of Cardiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, 226014, India.
Background: Aldosterone is categorized as a mineralocorticoid hormone produced in the zona glomerulosa of the adrenal cortex. Aldosterone has considerable action in sodium and water retention along with cardiac remodeling, promoting fibrosis and these detrimental effects have been counteracted by mineralocorticoid receptors antagonists over time. Spironolactone, a non-selective steroidal MRA used extensively is potent but has serious adverse effects like gynecomastia and hyperkalemia.
View Article and Find Full Text PDFNon-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.
Postgrad Med
March 2024
Department of Internal Medicine, Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Chronic kidney disease (CKD) is a prevalent complication of Type II diabetes (T2D). The coexistence of CKD with T2D is comparable to cardiovascular disease (CVD) when the estimated glomerular filtration rate declines below 60 ml/min/1.73 m.
View Article and Find Full Text PDFFinerenone - Halting Relative Hyperaldosteronism in Chronic Kidney Disease.
N Engl J Med
December 2020
From Tufts University School of Medicine, Boston, and the Center for Clinical and Translational Research, Maine Medical Center Research Institute, Scarborough (C.J.R.).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!